Drugs for Immunotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067281
  • December 2021
  • Pharmaceuticals
  • 214 Pages
Report Description

This report is a comprehensive study that examines the Drugs for Immunotherapy industry in depth. With reference to key regions and major nations, the study specifies the product type of Drugs for Immunotherapy as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Drugs for Immunotherapy market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Drugs for Immunotherapy market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Drugs for Immunotherapy market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Drugs for Immunotherapy Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Drugs for Immunotherapy market study. The market dynamics and factors such as the threat of a Drugs for Immunotherapy substitute, the threat of new entrants into the Drugs for Immunotherapy market, buyer bargaining power, supplier bargaining power to Drugs for Immunotherapy providing companies, and internal rivalry among Drugs for Immunotherapy providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Drugs for Immunotherapy market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Drugs for Immunotherapy industry.
 
Drugs for Immunotherapy Market Key Trends Analysis

The important factors influencing the growth of the Drugs for Immunotherapy market have been examined in this report. The driving factors that are boosting demand for Drugs for Immunotherapys and the restraining factors that are slowing growth of the Drugs for Immunotherapy industry are addressed in depth, as well as their implications for the worldwide Drugs for Immunotherapy market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Drugs for Immunotherapy Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Drugs for Immunotherapy industry. On the basis of current and future trends, all segments of the Drugs for Immunotherapy industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Drugs for Immunotherapy Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Drugs for Immunotherapy market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Drugs for Immunotherapy market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Drugs for Immunotherapy market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Drugs for Immunotherapy market. All important stakeholders in the Drugs for Immunotherapy value chain and technological ecosystem are expected to benefit from the insights offered in the Drugs for Immunotherapy market research study.

In order to provide a broader understanding of the top competitors in the Drugs for Immunotherapy market, the research includes a company market share analysis. F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc, AbbVie Inc, Merck & Co. Inc, GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac are among the major participants in the global Drugs for Immunotherapy industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc, AbbVie Inc, Merck & Co. Inc, GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac
 
Major Highlights of the Drugs for Immunotherapy Market report study:
  • An in-depth examination of the global Drugs for Immunotherapy industry will be published soon.
  • The study examines the global Drugs for Immunotherapy market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Drugs for Immunotherapy industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Drugs for Immunotherapy market is being shaped by several major trends.
  • The size of the Drugs for Immunotherapy market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Drugs for Immunotherapy market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Drugs for Immunotherapy market as follows:
Global Drugs for Immunotherapy Market: By Product Type

  • Monoclonal Antibodies
  • Interferons
  • Interleukins
  • Vaccines
  • Checkpoint Inhibitors
  • Others

Global Drugs for Immunotherapy Market: By Application
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Global Drugs for Immunotherapy Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Drugs for Immunotherapy market.
  • Universities and students
  • Other companies in the Drugs for Immunotherapy market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Drugs for Immunotherapy market

Manufacturers and Segments

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Amgen Inc
  • AbbVie Inc
  • Merck & Co. Inc
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • AstraZeneca plc
  • Johnson & Johnson
  • UbiVac
  • Monoclonal Antibodies
  • Interferons
  • Interleukins
  • Vaccines
  • Checkpoint Inhibitors
  • Others
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Drugs for Immunotherapy Market Snapshot
          2.1.1. Global Drugs for Immunotherapy Market By Monoclonal Antibodies,2019
               2.1.1.1.
               2.1.1.2.Monoclonal Antibodies
               2.1.1.3.Interferons
               2.1.1.4.Interleukins
               2.1.1.5.Vaccines
               2.1.1.6.Checkpoint Inhibitors
          2.1.2. Global Drugs for Immunotherapy Market By Hospitals & Clinics,2019
               2.1.2.1.
               2.1.2.2.Hospitals & Clinics
               2.1.2.3.Ambulatory Surgical Centers
          2.1.3. Global Drugs for Immunotherapy Market By End-use,2019
          2.1.4. Global Drugs for Immunotherapy Market By Geography,2019

3. Global Drugs for Immunotherapy Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Monoclonal Antibodies, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Monoclonal Antibodies, 2020
     4.2. Global Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028

5. Global Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Hospitals & Clinics, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Hospitals & Clinics, 2020
     5.2. Global Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028

6. Global Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028

7. Global Drugs for Immunotherapy Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Drugs for Immunotherapy Market Analysis, 2018 – 2028 
          7.2.1. North America Drugs for Immunotherapy Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028
          7.2.3. North America Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028
          7.2.4. North America Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Drugs for Immunotherapy Market Analysis, 2018 – 2028 
          7.3.1.  Europe Drugs for Immunotherapy Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028
          7.3.3. Europe Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028
          7.3.4. Europe Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Drugs for Immunotherapy Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Drugs for Immunotherapy Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028
          7.4.3. Asia Pacific Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028
          7.4.4. Asia Pacific Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Drugs for Immunotherapy Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Drugs for Immunotherapy Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028
          7.5.3. Latin America Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028
          7.5.4. Latin America Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Drugs for Immunotherapy Market Analysis, 2018 – 2028 
          7.6.1.  MEA Drugs for Immunotherapy Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Drugs for Immunotherapy Market Size (US$), By Monoclonal Antibodies, 2018 – 2028
          7.6.3. MEA Drugs for Immunotherapy Market Size (US$), By Hospitals & Clinics, 2018 – 2028
          7.6.4. MEA Drugs for Immunotherapy Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Drugs for Immunotherapy Providers
        8.4.1 F. Hoffmann-La Roche Ltd
                8.4.1.1 Business Description
                8.4.1.2 F. Hoffmann-La Roche Ltd Geographic Operations
                8.4.1.3 F. Hoffmann-La Roche Ltd Financial Information
                8.4.1.4 F. Hoffmann-La Roche Ltd Product Positions/Portfolio
                8.4.1.5 F. Hoffmann-La Roche Ltd Key Developments
        8.4.2 Novartis AG
                8.4.2.1 Business Description
                8.4.2.2 Novartis AG Geographic Operations
                8.4.2.3 Novartis AG Financial Information
                8.4.2.4 Novartis AG Product Positions/Portfolio
                8.4.2.5 Novartis AG Key Developments
        8.4.3 Amgen Inc
                8.4.3.1 Business Description
                8.4.3.2 Amgen Inc Geographic Operations
                8.4.3.3 Amgen Inc Financial Information
                8.4.3.4 Amgen Inc Product Positions/Portfolio
                8.4.3.5 Amgen Inc Key Developments
        8.4.4 AbbVie Inc
                8.4.4.1 Business Description
                8.4.4.2 AbbVie Inc Geographic Operations
                8.4.4.3 AbbVie Inc Financial Information
                8.4.4.4 AbbVie Inc Product Positions/Portfolio
                8.4.4.5 AbbVie Inc Key Developments
        8.4.5 Merck & Co. Inc
                8.4.5.1 Business Description
                8.4.5.2 Merck & Co. Inc Geographic Operations
                8.4.5.3 Merck & Co. Inc Financial Information
                8.4.5.4 Merck & Co. Inc Product Positions/Portfolio
                8.4.5.5 Merck & Co. Inc Key Developments
        8.4.6 GlaxoSmithKline
                8.4.6.1 Business Description
                8.4.6.2 GlaxoSmithKline Geographic Operations
                8.4.6.3 GlaxoSmithKline Financial Information
                8.4.6.4 GlaxoSmithKline Product Positions/Portfolio
                8.4.6.5 GlaxoSmithKline Key Developments
        8.4.7 Eli Lilly and Company
                8.4.7.1 Business Description
                8.4.7.2 Eli Lilly and Company Geographic Operations
                8.4.7.3 Eli Lilly and Company Financial Information
                8.4.7.4 Eli Lilly and Company Product Positions/Portfolio
                8.4.7.5 Eli Lilly and Company Key Developments
        8.4.8 Bristol-Myers Squibb
                8.4.8.1 Business Description
                8.4.8.2 Bristol-Myers Squibb Geographic Operations
                8.4.8.3 Bristol-Myers Squibb Financial Information
                8.4.8.4 Bristol-Myers Squibb Product Positions/Portfolio
                8.4.8.5 Bristol-Myers Squibb Key Developments
        8.4.9 AstraZeneca plc
                8.4.9.1 Business Description
                8.4.9.2 AstraZeneca plc Geographic Operations
                8.4.9.3 AstraZeneca plc Financial Information
                8.4.9.4 AstraZeneca plc Product Positions/Portfolio
                8.4.9.5 AstraZeneca plc Key Developments
        8.4.10 Johnson & Johnson
                8.4.10.1 Business Description
                8.4.10.2 Johnson & Johnson Geographic Operations
                8.4.10.3 Johnson & Johnson Financial Information
                8.4.10.4 Johnson & Johnson Product Positions/Portfolio
                8.4.10.5 Johnson & Johnson Key Developments
        8.4.11 UbiVac
                8.4.11.1 Business Description
                8.4.11.2 UbiVac Geographic Operations
                8.4.11.3 UbiVac Financial Information
                8.4.11.4 UbiVac Product Positions/Portfolio
                8.4.11.5 UbiVac Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Drugs for Immunotherapy Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Drugs for Immunotherapy Market Revenue, By Monoclonal Antibodies, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Drugs for Immunotherapy Market Revenue, By Hospitals & Clinics, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Drugs for Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Drugs for Immunotherapy Market Revenue, By Monoclonal Antibodies, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Drugs for Immunotherapy Market Revenue, By Hospitals & Clinics, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Drugs for Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Drugs for Immunotherapy Market Revenue, By Monoclonal Antibodies, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Drugs for Immunotherapy Market Revenue, By Hospitals & Clinics, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Drugs for Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Drugs for Immunotherapy Market Revenue, By Monoclonal Antibodies, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Drugs for Immunotherapy Market Revenue, By Hospitals & Clinics, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Drugs for Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Drugs for Immunotherapy Market Revenue, By Monoclonal Antibodies, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Drugs for Immunotherapy Market Revenue, By Hospitals & Clinics, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Drugs for Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Drugs for Immunotherapy: Market Segmentation 
FIG. 2 Global Drugs for Immunotherapy Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Drugs for Immunotherapy Market, By Monoclonal Antibodies, 2019 (US$ Mn) 
FIG. 5 Global Drugs for Immunotherapy Market, By Hospitals & Clinics, 2019 (US$ Mn) 
FIG. 6 Global Drugs for Immunotherapy Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Drugs for Immunotherapy Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Drugs for Immunotherapy Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Drugs for Immunotherapy Providers, 2019
FIG. 11 Global Drugs for Immunotherapy Market Revenue Contribution, By Monoclonal Antibodies, 2019 & 2028 (Value %) 
FIG. 12 Global Drugs for Immunotherapy Market Revenue Contribution, By Hospitals & Clinics, 2019 & 2028 (Value %) 
FIG. 13 Global Drugs for Immunotherapy Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Drugs for Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Drugs for Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Drugs for Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Drugs for Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Drugs for Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Drugs for Immunotherapy market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Drugs for Immunotherapy Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Drugs for Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE  North America Drugs for Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE  North America Drugs for Immunotherapy Market Value, By Country, 2018 – 2028
TABLE  Europe Drugs for Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE  Europe Drugs for Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE  Europe Drugs for Immunotherapy Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Drugs for Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Drugs for Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Drugs for Immunotherapy Market Value, By Country, 2018 – 2028
TABLE  Latin America Drugs for Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Drugs for Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Drugs for Immunotherapy Market Value, By Country, 2018 – 2028
TABLE  MEA Drugs for Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE  MEA Drugs for Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE  MEA Drugs for Immunotherapy Market Value, By Country, 2018 – 2028
TABLE  F. Hoffmann-La Roche Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amgen Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AbbVie Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck & Co. Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Johnson & Johnson: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  UbiVac: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Drugs for Immunotherapy Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Drugs for Immunotherapy Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Drugs for Immunotherapy Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Drugs for Immunotherapy Market, By Geography, 2019 (US$ Mn)
FIG.  Global Drugs for Immunotherapy Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Drugs for Immunotherapy Providers, 2016
FIG.  Global Drugs for Immunotherapy Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Monoclonal Antibodies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Interferons Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Interleukins Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Checkpoint Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Drugs for Immunotherapy Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Hospitals & Clinics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ambulatory Surgical Centers Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Drugs for Immunotherapy Market Value, 2018 – 2028, (US$ Mn)